子宫内膜癌（EC）是发达国家最常见的妇科恶性肿瘤，近年来我国的发病率亦逐年升高，并呈现年轻化趋势。随着国际指南不断更新，EC的诊断、治疗与随访已规范化。然而，临床实践中EC存在显著生物学异质性，仅依赖临床病理因素难以精准识别预后差异与治疗获益。因此，在规范化管理基础上，引入个体化策略成为必然趋势。癌症基因组图谱（TCGA）分型奠定了EC分子时代的框架，不同的分子亚型不仅具有显著预后差异，而且也能指导化疗、放疗及免疫治疗的选择。近年来，免疫微环境（TIME）研究快速发展，不同免疫浸润模式对治疗反应的影响逐渐明确。文章简述EC规范化诊疗的现状与进展，并重点讨论分子分型、免疫特征、多组学整合等驱动的个体化策略，以期为临床实践提供参考。

Endometrial cancer （EC） is the most common gynecologic malignancy in developed countries，and its incidence has been steadily increasing in recent years in China，with a trend toward younger onset. With the updates of international guidelines，the diagnosis，treatment and follow-up of EC have entered an era of high standardization. However，EC exhibits marked biological heterogeneity in clinical practice，and reliance solely on clinicopathological factors is insufficient in accurately identifying prognostic differences and predicting therapeutic benefit. Therefore，the introduction of individualized strategies on the basis of standardized management has become an inevitable trend. The TCGA classification has established the framework for the molecular era of EC，with distinct molecular subtypes showing significant prognostic differences and providing guidance for the selection of chemotherapy，radiotherapy and immunotherapy. In recent years，rapid advances in researches on the tumor immune microenvironment （TIME） have further clarified the impact of different immune infiltration patterns on treatment responses. This review summarizes the current status and recent advances in standardized diagnosis and treatment of EC，with a particular focus on individualized strategies driven by molecular typing，immune characteristics，and multi-omics integration，aiming to provide references for clinical practice.